Yiviva Announces Dosing of First Patient in Phase 2b Study of First-Line YIV-906 Plus Sorafenib Combination Therapy in the Treatment of Hepatocellular Carcinoma

NEXT STORY
Myriad Receives Reimbursement for the BRACAnalysis® Diagnostic System in Japan for Patients with Breast or Ovarian Cancer Associated with HBOC
PREV STORY
RedHill Biopharma Announces First COVID-19 Patient Treated with Opaganib in Israel Under Compassionate Use
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

DUBLIN, Ireland, May 30, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), today announced ...

author_avatar
NASDAQ Market News

GW Pharmaceuticals to Present at the Piper Jaffray 27th Annual Healthcare Conference

LONDON, Nov. 24, 2015 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or ...

author_avatar
NASDAQ Market News

ABLYNX ANNOUNCES WARRANT EXERCISE

REGULATED INFORMATION GHENT, Belgium, 17 May 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] ...

author_avatar
NASDAQ Market News